<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550859</url>
  </required_header>
  <id_info>
    <org_study_id>YMC030</org_study_id>
    <nct_id>NCT03550859</nct_id>
  </id_info>
  <brief_title>HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria</brief_title>
  <official_title>Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney
      disease patients with proteinuria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change from baseline to week 48 in Urine Protein to Creatinine Ratio (UPCR)</measure>
    <time_frame>baseline, week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in UPCR</measure>
    <time_frame>baseline, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 and week 48 in Urine Albumin-to-Creatinine Ratio (UACR)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 and week 48 in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in UPCR</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in high-sensitivity CRP (hs-CRP)</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in HOMA-insulin resistance (HOMA-IR)</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in 24hr urine protein</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose UPCR decreased by more than 30% at 48 weeks</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in MCP-1 (monocyte chemoattractant protein 1)</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in urinary 8-isoprostane</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in urine nephrin</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in type IV collagen</measure>
    <time_frame>baseline, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who received renal replacement therapy (dialysis or renal transplant) at 12, 24, 36, or 48 weeks</measure>
    <time_frame>baseline, week 12, week 24, week 36, week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Duowell Tab. 40/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micardis Tab. 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 40mg qd for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Rosuvastatin 40/10mg</intervention_name>
    <description>Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks</description>
    <arm_group_label>Duowell Tab. 40/10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40mg</intervention_name>
    <description>Telmisartan 40mg qd for 48 weeks</description>
    <arm_group_label>Micardis Tab. 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged ≥ 19 years

          2. Chronic Kidney Disease (CKD) with CKD stage G2 or G3 and 300 mg/g ≤ urine PCR ≤ 3000
             mg/g

          3. Diagnosed with hypertension

          4. Written informed consent

          5. Patients who have not administered statin (including rosuvastatin) and hyperlipidemia
             treatment for at least 4 weeks prior to randomization

        Exclusion Criteria:

          1. Type I diabetes

          2. Uncontrolled diabetic patients with HbA1c &gt; 10% at screening

          3. Hypertensive patients whose mean blood pressure was not controlled at 160/90 mmHg or
             more in triplicate despite the use of antihypertensive agents at the time of
             randomization

          4. Calculated LDL-C ≥ 160 mg/dL at randomization

          5. Patients who have taken RAS blockers (ACE inhibitor, ARB, and Aldosterone antagonist)
             for 4 weeks prior to randomization

          6. Heart failure patients with NYHA class IV

          7. Patients with acute and chronic liver disease, acute inflammation, hematologic
             abnormalities and cancer within the last 6 months

          8. Patients with a history of cerebral blood cardiovascular complications (cerebral
             infarction, transient ischemic attack, myocardial infarction, unstable angina,
             coronary artery bypass, and percutaneous coronary intervention)

          9. Patients taking immunosuppressive drugs

         10. Patients undergoing eGFR &lt;30 mL/min/1.73 m2 (CKD-EPI formula) or renal replacement
             therapy (dialysis or renal transplant) at screening

         11. Patients with a change in eGFR (CKD-EPI formula) value showing a difference of more
             than 30% in the last 6 months at screening

         12. Creatine kinase (CK) level ≥ 3x ULN (upper limit of normal range)

         13. Patients who are pregnant or planning to become pregnant

         14. Contraindications stated in the SPC of telmisartan or rosuvastatin

         15. Those participating in other clinical trials for investigational products at screening

         16. Patients deemed to be ineligible to participate in the trial by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>InJyung Kim</last_name>
      <phone>+82-33-749-0937</phone>
      <email>noblessik@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>ByungGeun Han, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangMi Oh</last_name>
      <phone>+82-31-380-1770</phone>
      <email>jinmi0320@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Seong-Gyun Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunJin Cho</last_name>
      <phone>+82-31-787-7030</phone>
      <email>10871@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Ki-Young Na, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangMin Lee</last_name>
      <phone>+82-31-412-6764</phone>
      <email>3blue9@naver.com</email>
    </contact>
    <investigator>
      <last_name>DaeRyong Cha, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YunJeong Chae</last_name>
      <phone>+82-63-250-1284</phone>
      <email>cyj70105@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Wok Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HwaYoung Lee</last_name>
      <phone>+82-53-200-6947</phone>
      <email>dlghkdud1225@naver.com</email>
    </contact>
    <investigator>
      <last_name>SunHee Park, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SeongJin Hong</last_name>
      <phone>+82-42-280-6948</phone>
      <email>hsj0674@cnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>DaeEun Choi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HeeJaa Lee</last_name>
      <phone>+82-31-910-7776</phone>
      <email>heejaalee@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sang-Youb Han, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SoonGuem Lee</last_name>
      <phone>+82-32-280-5188</phone>
      <email>endo-zzang@daum.net</email>
    </contact>
    <investigator>
      <last_name>SeokJoon Shin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Center</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MiRan Choi</last_name>
      <phone>+82-2-829-5215</phone>
      <email>hellocherry@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Young-Ki Lee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>korea Universitiy Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KyungHee Universitiy Hospital at Gandong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiHyun Kim</last_name>
      <phone>+82-2-440-7065</phone>
      <email>cell41@naver.com</email>
    </contact>
    <investigator>
      <last_name>Ju Young MOON, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiYoung Kim</last_name>
      <phone>+82-2-870-3875</phone>
      <email>smile0212@daum.net</email>
    </contact>
    <investigator>
      <last_name>Chun Soo Lim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

